Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Single-blind, Single-center, Placebo-controlled First-in-human Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RBD2080 in Healthy Participants

NCT07869940 is registered in ClinicalTrials.gov with Suzhou Ribo Life Science Co. Ltd. as lead sponsor.

NCT NCT07869940
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07869940 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Single-blind, Single-center, Placebo-controlled First-in-human Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RBD2080 in Healthy Participants
Lead sponsor
Suzhou Ribo Life Science Co. Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
August 19, 2026
Completion date
March 31, 2028
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy